What is the recommended inpatient treatment for a hospitalized patient with a penicillin allergy who has an Escherichia coli urinary tract infection?

Treatment of E. coli UTI in Hospitalized Patients with Penicillin Allergy

For a hospitalized patient with penicillin allergy and E. coli UTI, use intravenous fluoroquinolones (ciprofloxacin 400 mg twice daily or levofloxacin 750 mg daily) as first-line therapy if local resistance is <10%, or alternatively use an aminoglycoside (gentamicin 5 mg/kg daily or amikacin 15 mg/kg daily) as monotherapy or with aztreonam. 1

Initial Empiric Treatment Approach

The treatment strategy depends critically on whether this is uncomplicated pyelonephritis versus complicated UTI, as the European Association of Urology 2024 guidelines provide distinct recommendations for each scenario 1:

For Uncomplicated Pyelonephritis (if applicable)

Fluoroquinolones are the preferred option when penicillins and cephalosporins cannot be used 1:

• Ciprofloxacin 400 mg IV twice daily 1
• Levofloxacin 750 mg IV once daily 1

Aminoglycosides represent an alternative, though not studied as monotherapy in uncomplicated pyelonephritis 1:

• Gentamicin 5 mg/kg IV once daily 1
• Amikacin 15 mg/kg IV once daily 1

For Complicated UTI (hospitalized patients often fall into this category)

The 2024 EAU guidelines specifically address penicillin allergy scenarios 1:

Ciprofloxacin is recommended ONLY if 1:

• Local resistance rate is <10%
• Patient has anaphylaxis to β-lactam antimicrobials
• Patient has not used fluoroquinolones in the last 6 months 1

If fluoroquinolones cannot be used, the guidelines recommend 1:

• Aminoglycoside monotherapy (gentamicin 5 mg/kg daily or amikacin 15 mg/kg daily) 1
• Consider adding aztreonam if broader coverage needed, as this is a β-lactam that does NOT cross-react with penicillin allergy 2

Critical Considerations for Penicillin Allergy

Most reported penicillin allergies are not true allergies 2. A 2015 study demonstrated that implementing a graded challenge protocol in hospitalized patients with reported penicillin allergy:

• Increased β-lactam test doses 7-fold without increased adverse reactions 2
• Reduced alternative antibiotic use including vancomycin, aztreonam, aminoglycosides, and fluoroquinolones 2
• Had only 3.9% adverse drug reaction rate during test doses 2

Consider allergy assessment before defaulting to alternatives, particularly if the allergy history is remote or unclear 2.

Treatment Duration

Duration should be 7-14 days depending on clinical factors 1:

• 7 days minimum for complicated UTI 1
• 14 days for men when prostatitis cannot be excluded 1
• Shorter duration (7 days) acceptable if patient is hemodynamically stable and afebrile for ≥48 hours 1
• For fluoroquinolones specifically: 5-7 days for pyelonephritis 1
• For β-lactams (if allergy ruled out): 7 days 1

Transition to Oral Therapy

Once clinically stable (afebrile ≥48 hours, hemodynamically stable), transition to oral therapy based on susceptibilities 1:

Oral fluoroquinolone options (if susceptible and local resistance <10%) 1:

• Ciprofloxacin 500-750 mg twice daily 1
• Levofloxacin 750 mg once daily 1

Essential Diagnostic Steps

Obtain urine culture and susceptibility testing before initiating antibiotics 1, 3:

• Urine cultures are positive in 90% of pyelonephritis cases 3
• Tailor therapy once susceptibilities return 1
• Blood cultures should be obtained if diagnosis uncertain, patient immunocompromised, or hematogenous infection suspected 3

Imaging considerations 1:

• Ultrasound to rule out obstruction in patients with urolithiasis history, renal dysfunction, or high urine pH 1
• CT scan if patient remains febrile after 72 hours or clinical deterioration 1

Common Pitfalls to Avoid

Do NOT use fluoroquinolones empirically if 1:

• Patient is from urology department 1
• Patient used fluoroquinolones in last 6 months 1
• Local resistance exceeds 10% 1

Avoid these agents for pyelonephritis 1:

• Nitrofurantoin (insufficient efficacy data) 1
• Oral fosfomycin (insufficient efficacy data) 1
• Pivmecillinam (insufficient efficacy data) 1

Address underlying complicating factors 1:

• Manage any urological abnormality 1
• Remove or replace urinary catheters if present 1

Risk Factors for Resistance

Higher risk of resistant organisms in 1:

• Healthcare-associated infections 1
• Recent antibiotic exposure 1
• Presence of foreign bodies or catheters 1
• Male patients 4
• Long-term care facility residents 4

In these scenarios, consider broader coverage with carbapenems or novel agents only if early culture results indicate multidrug-resistant organisms 1.